175 related articles for article (PubMed ID: 35759653)
1. Early human B cell signatures of the primary antibody response to mRNA vaccination.
Kardava L; Rachmaninoff N; Lau WW; Buckner CM; Trihemasava K; Blazkova J; Lopes de Assis F; Wang W; Zhang X; Wang Y; Chiang CI; Narpala S; McCormack GE; Liu C; Seamon CA; Sneller MC; O'Connell S; Li Y; McDermott AB; Chun TW; Fauci AS; Tsang JS; Moir S
Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2204607119. PubMed ID: 35759653
[TBL] [Abstract][Full Text] [Related]
2. Pre-vaccination and early B cell signatures predict antibody response to SARS-CoV-2 mRNA vaccine.
Kardava L; Rachmaninoff N; Lau WW; Buckner CM; Trihemasava K; de Assis FL; Wang W; Zhang X; Wang Y; Chiang CI; Narpala S; Reger R; McCormack GE; Seamon CA; Childs RW; Suffredini AF; Strich JR; Chertow DS; Davey RT; Sneller MC; O'Connell S; Li Y; McDermott A; Chun TW; Fauci AS; Tsang JS; Moir S
medRxiv; 2021 Jul; ():. PubMed ID: 34268520
[TBL] [Abstract][Full Text] [Related]
3. mRNA-based SARS-CoV-2 Comirnaty vaccine elicits weak and short specific memory B cell response in individuals with no previous infection.
Casado JL; Vizcarra P; Martín-Hondarza A; Gómez-Maldonado S; Muedra-Sánchez M; Del Pino J; Mirabella IG; Martín-Colmenarejo S; Haemmerle J; Fernández-Escribano M; Vallejo A
Front Immunol; 2023; 14():1127379. PubMed ID: 37457694
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
Front Immunol; 2022; 13():811020. PubMed ID: 35126395
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
[TBL] [Abstract][Full Text] [Related]
6. Six-month longitudinal immune kinetics after mRNA-1273 vaccination: Correlation of peak antibody response with long-term, cross-reactive immunity.
Choi MJ; Heo JY; Seo YB; Yoon YK; Sohn JW; Noh JY; Cheong HJ; Kim WJ; Choi JY; Kim HJ; Lee YJ; Lee HW; Kim SS; Kim B; Song JY
Front Immunol; 2022; 13():1035441. PubMed ID: 36700198
[TBL] [Abstract][Full Text] [Related]
7. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
[TBL] [Abstract][Full Text] [Related]
8. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
9. High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines.
Pape KA; Dileepan T; Kabage AJ; Kozysa D; Batres R; Evert C; Matson M; Lopez S; Krueger PD; Graiziger C; Vaughn BP; Shmidt E; Rhein J; Schacker TW; Khoruts A; Jenkins MK
Cell Rep; 2021 Oct; 37(2):109823. PubMed ID: 34610291
[TBL] [Abstract][Full Text] [Related]
10. Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort.
Beilhack G; Monteforte R; Frommlet F; Gaggl M; Strassl R; Vychytil A
Front Immunol; 2021; 12():780594. PubMed ID: 34925359
[TBL] [Abstract][Full Text] [Related]
11. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
Front Immunol; 2021; 12():737083. PubMed ID: 34539673
[TBL] [Abstract][Full Text] [Related]
12. Tracking B cell responses to the SARS-CoV-2 mRNA-1273 vaccine.
Lopes de Assis F; Hoehn KB; Zhang X; Kardava L; Smith CD; El Merhebi O; Buckner CM; Trihemasava K; Wang W; Seamon CA; Chen V; Schaughency P; Cheung F; Martins AJ; Chiang CI; Li Y; Tsang JS; Chun TW; Kleinstein SH; Moir S
Cell Rep; 2023 Jul; 42(7):112780. PubMed ID: 37440409
[TBL] [Abstract][Full Text] [Related]
13. S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit.
Nguyen-Contant P; Embong AK; Kanagaiah P; Chaves FA; Yang H; Branche AR; Topham DJ; Sangster MY
mBio; 2020 Sep; 11(5):. PubMed ID: 32978311
[TBL] [Abstract][Full Text] [Related]
14. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2-Specific Memory B Cell Responses Are Maintained After Recovery from Natural Infection and Postvaccination.
Moore T; Hossain R; Doores KJ; Shankar-Hari M; Fear DJ
Viral Immunol; 2022 Jul; 35(6):425-436. PubMed ID: 35857310
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
Front Immunol; 2022; 13():846753. PubMed ID: 35309297
[TBL] [Abstract][Full Text] [Related]
17. mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals.
Longet S; Hargreaves A; Healy S; Brown R; Hornsby HR; Meardon N; Tipton T; Barnes E; Dunachie S; Duncan CJA; Klenerman P; Richter A; Turtle L; de Silva TI; Carroll MW
Front Immunol; 2022; 13():953949. PubMed ID: 36159846
[TBL] [Abstract][Full Text] [Related]
18. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
[TBL] [Abstract][Full Text] [Related]
20. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D
Front Immunol; 2022; 13():1017863. PubMed ID: 36248803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
